Showing papers on "Stem-cell therapy published in 2000"
TL;DR: The promising gene therapy application of adult stem and progenitor cells in terms of modifying stem cell potency, altering organ property, accelerating regeneration and forming expressional organization is discussed.
Abstract: The committed stem and progenitor cells have been recently isolated from various adult tissues, including hematopoietic stem cell, neural stem cell, mesenchymal stem cell and endothelial progenitor cell. These adult stem cells have several advantages as compared with embryonic stem cells as their practical therapeutic application for tissue regeneration. In this review, we discuss the promising gene therapy application of adult stem and progenitor cells in terms of modifying stem cell potency, altering organ property, accelerating regeneration and forming expressional organization.
211 citations
TL;DR: It is concluded that the reinfusion of donor stem cells is frequently successful in achieving engraftment with rare occurrence of fatal GVHD and relatively good long-term survival was demonstrated.
Abstract: In this study we retrospectively evaluated the effect and outcome of a boost dose of donor stem cells without additional chemotherapy or total body irradiation. Between March 1983 and August 1999, 20
27 citations
TL;DR: Experimental data indicate that rats suffering from florid chronic progressive systemic arthritis or from chronic remitting/relapsing encephalomyelitis with autologous bone marrow transplantation (BMT) is highly effective but that the patients should be subjected to a conditioning regimen that induces maximal lymphoablation and that the autOLOGous transplant has to be T-cell depleted.
Abstract: Treatment of rats suffering from florid chronic progressive systemic arthritis or from chronic remitting/relapsing encephalomyelitis with autologous bone marrow transplantation (BMT) is highly effective. This finding was unexpected as the genotype of the bone marrow largely determines the susceptibility of both spontaneous and induced autoimmune diseases in rodents. The success of autologous stem-cell transplantation depends on the completeness of eradication of the effectors of autoimmune disease, in other words activated and memory T lymphocytes. The reviewed experimental data, when translated to the clinic, indicate that the patients should be subjected to a conditioning regimen that induces maximal lymphoablation and that the autologous transplant has to be T-cell depleted.
15 citations
TL;DR: In this review the broad therapeutic implications as well as potentials and limitations of this technique are summarized and a prospective view concerning experimental and clinical future perspectives including the possibility for gene therapy is presented.
Abstract: In utero stem cell transplantation represents a new and still experimental therapeutic strategy for diseases related to the hematopoietic system, i.e. hemoglobinopathies, immunodeficiency diseases and metabolic disorders. To date, a total of 21 cases of transplantations using stem cells either of fetal liver or adult bone marrow origin have been reported in the literature. Success has been limited--with the exception of one case of beta-thalassemia--to four cases with immunodeficiency diseases. In this review the broad therapeutic implications as well as potentials and limitations of this technique are summarized. Furthermore, ethical considerations based on the use of fetal cells are pointed out and a prospective view concerning experimental and clinical future perspectives including the possibility for gene therapy is presented.
14 citations
TL;DR: Three therapeutic strategies are discussed that pursue the hypothesis that a stable cure of autoimmune disease can only be expected if the patient’s autoreactive immunocompetent cells are replaced by cells that are not autore active.
Abstract: Estimates of the prevalence of autoimmune diseases range from 3 to 7%, and the treatment of a minority of these patients with severe progressive disease is not satisfactory. It has been recognized that the autoimmune basis of human disease results from the failure of multiple components of the immune system, but the most frequently used criteria to establish the autoimmune nature of a disease is the presence of defined reactions against self-antigens as a major component in the pathophysiology. This concept gave rise to the hypothesis that a stable cure of autoimmune disease can only be expected if the patient’s autoreactive immunocompetent cells are replaced by cells that are not autoreactive. In this issue of Arthritis Research, three therapeutic strategies are discussed that pursue this goal: allogeneic hematopoietic stem–cell transplantation, autologous hematopoietic stemcell therapy following intensive suppression, and intense immune suppression alone [1–3].
11 citations
Journal Article•
TL;DR: Studies have now been initiated to demonstrate the feasibility of generating enough cells to fully reconstitute hematopoiesis from small volumes of cellular progenitors, and it has been demonstrated that tumor cell contamination passively decreases during the culture period.
Abstract: The expansion of human stem cells and their genetic manipulation represent areas of increasing interest in the field of stem cell transplantation. Previously, stem cell transplantation has been accomplished by using cellular products obtained by large volume bone marrow or peripheral blood harvest. Difficulties with this approach include inadequate cell numbers and tumor cell contamination. Furthermore, for gene transfer modalities requiring proliferating progenitor cells, low gene expression would be expected in these products. To address these difficulties, the AastromReplicell System has been developed as a fully closed and automated system for expanding hematopoietic cells. Investigators at Aastrom have evaluated the conditions needed for optimal growth including the need for unpurified bone marrow or cord blood mononuclear cells, high cell densities, serum-containing medium and certain types of plastic surfaces. Studies have now been initiated to demonstrate the feasibility of generating enough cells to fully reconstitute hematopoiesis from small volumes of cellular progenitors. It has also been demonstrated that tumor cell contamination passively decreases during the culture period. It now remains to be shown in a direct comparison that this approach yields greater efficacy and a lower cost than transplantation with unmanipulated large volume marrow or peripheral blood stem cell products.
1 citations
TL;DR: In this supplement, recent findings are discussed that have major implications for the conventional concept of hematopoiesis and lead to paradigm shifts in this field.
1 citations
TL;DR: This volume represents some of the most important and most recent thoughts on the particular viral infections of great significance to the stem cell therapy patient and how those infections ought to be managed.
Abstract: A meeting on April 29, 1999, in Wilmington, Delaware, examined a variety of important issues related to viral infections in patients undergoing hemaopoietic stem cell transplants. This volume represents some of the most important and most recent thoughts on the particular viral infections of great significance to the stem cell therapy patient and how those infections ought to be managed. This paper provides an introduction to the subjects discussed, presents the problem areas and summarizes the meeting objectives.